Magen BioSciences Inc. is using its co-founder's new research findings on the signaling pathways underlying the production of melanin to develop drugs for disfiguring dermatological pigmentation disorders. Some of its treatments could also be developed for the cosmetics market, including skin lightening or sunless tanning products, where revenues could exceed the prescription market.
Neosil Inc. intends to develop NCEs for unmet needs in dermatology. The company will select product candidates at an early...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?